Elevated Plasma Procoagulant and Fibrinolytic Markers in Patients with Chronic Obstructive Pulmonary Disease

Access this Article

Author(s)

Abstract

<i>Objective</i> There is clinical and pathological evidence of thrombosis in pulmonary vessels of patients with chronic obstructive pulmonary disease (COPD). The purpose of this study was to investigate the presence of hypercoagulability and determine the extent of this abnormality in COPD patients.<br> <i>Patients and Methods</i> We measured plasma levels of thrombin antithrombin III complex (TAT), fibrinopeptide A (FPA), tissue plasminogen activator-plasminogen activator inhibitor (tPA-PAI): markers of coagulation-fibrinolysis-system, and also β-thromboglobulin (β-TG): a marker of platelet activation, in 40 COPD patients and in 20 control subjects. Measurements were also repeated 12 months after entry in all patients.<br> <i>Results</i> TAT, FPA, tPA-PAI, and β-TG concentrations were significantly higher in COPD than in control subjects. At 12 months follow-up, ΔA-aDO<sub>2</sub> and Δ%FEV<sub>1</sub> were significantly higher in patients with high TAT or tPA-PAI levels than in patients with low levels and TAT, FPA and tPA-PAI levels remained elevated, although β-TG levels decreased after domiciliary O<sub>2</sub> therapy.<br> <i>Conclusion</i> Our results showed an enhanced prothrombotic process in COPD patients, which could potentially account for the increased thrombosis in pulmonary vessels in these patients.<br>(Internal Medicine 41:181-185, 2002)

Journal

  • Internal Medicine

    Internal Medicine 41(3), 181-185, 2002-03

    The Japanese Society of Internal Medicine

References:  28

Keywords

Codes

  • NII Article ID (NAID)
    10008034370
  • NII NACSIS-CAT ID (NCID)
    AA10827774
  • Text Lang
    ENG
  • Article Type
    ART
  • ISSN
    09182918
  • NDL Article ID
    6262754
  • NDL Source Classification
    ZS21(科学技術--医学--内科学)
  • NDL Call No.
    Z53-M398
  • Data Source
    CJP  NDL  J-STAGE 
Page Top